Navigation Links
Spherix to Exhibit at the BIO 2009 International Convention
Date:5/14/2009

tatements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of Naturlose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop Naturlose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our current report on Form 8-K filed on October 10, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Spherix Reports 3rd Quarter Earnings
3. Spherix Reports 2007 Financial Results
4. Spherix Hires Key Employees
5. Spherix Holds Annual Shareholders Meeting
6. Spherix Reports 1st Quarter Earnings
7. Spherix Receives NASDAQ Bid Price Deficiency Letter
8. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
9. Spherix Transfers Stock Listing to Nasdaq Capital Market
10. Spherix Reports 3rd Quarter Earnings
11. Spherix Announces 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... March 25, 2015 Data from ... Mechanism of Action in Neuromuscular Diseases , ... Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication of ... troponin activator tirasemtiv in the journal Neurotherapeutics. ... “Evidence of Effect” or hypothesis-generating clinical trial which ...
(Date:3/25/2015)... 25, 2015  The Technology Association of ... to the promotion and economic advancement of ... as one of its Top 40 Innovative Technology Companies ... this prestigious group at the 2015 Georgia Technology Summit ... Centre. TAG,S Top 40 Awards recognize ...
(Date:3/25/2015)... 2015 Proove Biosciences , a ... to announce the success of their commercially supported symposium, ... to Optimize the Management of Pain, at the 31st ... Harbor, Maryland on Thursday, March 19th, 2015. ... President Lynn Webster , M.D., former Florida Society ...
(Date:3/25/2015)... The global Smart Weapons Market ... products, technology, platform, and geography. The various ... laser, infra-red, microwave, global positioning systems, and ... mapping systems, and inertial navigation systems. , ... Figures spread through 172 Pages and in-depth ...
Breaking Biology Technology:Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 2Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 3Streamline Health, Inc. Named a TAG Top 40 Innovative Technology Company 4Proove Biosciences Hosts Symposium on Incorporating Genetic Testing to Optimize the Management of Pain 2Smart Weapons Market is Estimate to reach $6.1 Billion by 2020 Worth $6.1 Billion by 2020 - New Report by MarketsandMarkets 2Smart Weapons Market is Estimate to reach $6.1 Billion by 2020 Worth $6.1 Billion by 2020 - New Report by MarketsandMarkets 3
... PRINCETON, N.J., Jun. 25 The U.S. ... Cardiovascular and Renal Drugs,voted to recommend the ... Inc.,s (OPDC) investigational treatment,for patients with hyponatremia., ... Advisory Committee supports the,potential approval of tolvaptan, ...
... Creation of Clear Regulatory Pathway Would Also Lower Total,Expenditures ... WASHINGTON, June 25 The Congressional Budget,Office (CBO) today ... an,abbreviated pathway for follow-on biologics -- or biogenerics -- ... and lower total,expenditures for biologics by $25 billion over ...
... - ProMetic Life Sciences Inc.,(TSX:PLI) ("ProMetic") announced ... of the prion capture resins developed by ... the removal of prions from,different solutions, including ... proteins such as 25% albumin and 3%,immunoglobulin ...
Cached Biology Technology:U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia 2CBO: Biogenerics Would Save Federal Government $6.6 Billion Over Ten Years 2ProMetic Further Confirms Performance of Prion Capture Resin at the Recovery of Biological Products Conference 2ProMetic Further Confirms Performance of Prion Capture Resin at the Recovery of Biological Products Conference 3
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... campaign on CNBC television starting March 30 th . ... airing in New York markets. ... "We are excited about our new ad campaign following the ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
(Date:3/17/2015)... March 17, 2015 Emotient, the leader ... today announced general availability of Emotient Analytics ... the analysis of facial expressions. The system analyzes ... content, products and services. It delivers audience response ... sentiment - as derived from facial evidence of ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... thousands of chemicals found in the environment may be ... disease is becoming easier because of a new field ... today by the National Academies of Sciences (NAS) recognizes ... health and recommends the integration of toxicogenomics into regulatory ...
... -- (Oct. 10, 2007) -- A few came. They ran. ... U.S. Marine Corp begins training in 2008 in new running ... of Oregon,s environmental chamber. The experience was enough to ... proud. UO researchers were unaware that it was InSport,s training ...
... A new book by researchers at the Hebrew ... mouse demonstrates a surprising similarity between mice and humans. ... a team from the Hebrew University Bone Laboratory consisting of ... and Dr. Yankel Gabet. Also participating in the writing of ...
Cached Biology News:NAS report offers new tools to assess health risks from chemicals 2Marines land at UO, leave with plans to wear Oregon-made training suits 2Marines land at UO, leave with plans to wear Oregon-made training suits 3Of mice and men: similarities between skeletons of both 2
... PEP-165 is an 18 amino acid synthetic peptide whose sequences ... peptide is (amino to carboxy terminus): S(21) - S - M ... D - E - A - I - D - K ... C(39). This peptide may be used for neutralization and ...
... microarrays designed for quantitative assays using ... built on the flexible and powerful ... customer specified sequences can be synthesized ... assistance with custom sequence design. These ...
... Neutralizing synthetic peptide for OPA1-01009, OPEP-01009 is a 16 amino ... human DNA fragmentation factor (DFF). The sequence of this ... P - K - S - V - K - ... S - P - R - K(18). This ...
... Tissue Arrays are intended for laboratory research ... fixed in neutral buffered formalin and embedded ... was performed by certified pathologists. Tissue ... and relocated into a new recipient paraffin ...
Biology Products: